ciprofloxacin has been researched along with Lung Diseases in 46 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Lung Diseases: Pathological processes involving any part of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis." | 9.17 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. ( Alder, J; De Soyza, A; Greville, H; Hampel, B; O'Donnell, A; Polverino, E; Reimnitz, P; Welte, T; Wilson, R, 2013) |
| "In order to evaluate the clinical efficacy and safety of oral ciprofloxacin in the treatment of acute pulmonary exacerbations of cystic fibrosis and trace the possible development of resistance over time, three trials were conducted." | 9.06 | Use of ciprofloxacin in cystic fibrosis patients. ( Bosso, JA, 1989) |
| "Ciprofloxacin has potent in vitro activity against Pseudomonas aeruginosa and Pseudomonas cepacia strains isolated from cystic fibrosis patients." | 9.06 | Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ( Blumer, JL; Goldfarb, J; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1987) |
| "Twenty adult patients with cystic fibrosis who were experiencing acute pulmonary exacerbations were enrolled in a randomized, controlled trial comparing oral ciprofloxacin with intravenous tobramycin plus azlocillin." | 9.06 | Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. ( Black, PG; Bosso, JA; Matsen, JM, 1987) |
| " We report an 18-year-old young woman with cystic fibrosis who experienced a pronounced decline in renal function after oral treatment with ciprofloxacin for 3 weeks." | 7.71 | Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis. ( Bald, M; Nikolaizik, W; Ratjen, F; Wingen, AM, 2001) |
| "The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied." | 7.68 | Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. ( Bryan, LE; Diver, JM; Rabin, HR; Schollaardt, T; Thorson, C, 1991) |
| "Twenty patients (17-27 yr) with cystic fibrosis were given ciprofloxacin at 30 pulmonary infectious exacerbations." | 7.67 | Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. ( Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1989) |
| "Ciprofloxacin is a major advance in the treatment of bronchopulmonary infection in patients with cystic fibrosis." | 6.66 | Ciprofloxacin therapy in cystic fibrosis. ( Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE, 1987) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 5.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| "Ciprofloxacin was administered orally (15 mg/kg of body weight) or intravenously (6 mg/kg) twice a day for at least 10 days during separate treatment periods." | 5.28 | Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ( Christensson, BA; Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1992) |
| "This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis." | 5.17 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. ( Alder, J; De Soyza, A; Greville, H; Hampel, B; O'Donnell, A; Polverino, E; Reimnitz, P; Welte, T; Wilson, R, 2013) |
| "In order to evaluate the clinical efficacy and safety of oral ciprofloxacin in the treatment of acute pulmonary exacerbations of cystic fibrosis and trace the possible development of resistance over time, three trials were conducted." | 5.06 | Use of ciprofloxacin in cystic fibrosis patients. ( Bosso, JA, 1989) |
| "Ciprofloxacin has potent in vitro activity against Pseudomonas aeruginosa and Pseudomonas cepacia strains isolated from cystic fibrosis patients." | 5.06 | Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ( Blumer, JL; Goldfarb, J; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1987) |
| "Twenty adult patients with cystic fibrosis who were experiencing acute pulmonary exacerbations were enrolled in a randomized, controlled trial comparing oral ciprofloxacin with intravenous tobramycin plus azlocillin." | 5.06 | Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. ( Black, PG; Bosso, JA; Matsen, JM, 1987) |
| " In cystic fibrosis-associated acute exacerbations of chronic pseudomonal pneumonitis, the outcome of oral ciprofloxacin therapy was very satisfactory in the six major studies reported (approximately 85% improvement rates)." | 4.77 | Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections. ( Bayer, AS, 1989) |
| " Neutropenia and thrombocytopenia associated with cefoxitin developed in 33 (51%) and 4 (6%) patients, respectively." | 3.75 | Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. ( Jeon, K; Kim, BJ; Kim, CK; Koh, WJ; Kook, YH; Kwon, OJ; Lee, NY; Lee, SH; Park, YK, 2009) |
| " We report an 18-year-old young woman with cystic fibrosis who experienced a pronounced decline in renal function after oral treatment with ciprofloxacin for 3 weeks." | 3.71 | Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis. ( Bald, M; Nikolaizik, W; Ratjen, F; Wingen, AM, 2001) |
| "The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied." | 3.68 | Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. ( Bryan, LE; Diver, JM; Rabin, HR; Schollaardt, T; Thorson, C, 1991) |
| "Twenty patients (17-27 yr) with cystic fibrosis were given ciprofloxacin at 30 pulmonary infectious exacerbations." | 3.67 | Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. ( Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1989) |
| "Ciprofloxacin is a major advance in the treatment of bronchopulmonary infection in patients with cystic fibrosis." | 2.66 | Ciprofloxacin therapy in cystic fibrosis. ( Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE, 1987) |
| " Ciprofloxacin dosed in identical fashion displayed rapid clearance with a half-life of approximately 30 min." | 1.48 | Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections. ( Chen, J; Convertine, AJ; Lee, B; Ratner, DM; Skerrett, SJ; Srinivasan, S; Stayton, PS; Su, FY; West, TE, 2018) |
| "Sepsis is a life-threatening disease resulted from a dysregulated host immune response to bacterial infections, continuing to cause high morbidity and mortality worldwide." | 1.48 | Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management. ( Gao, J; Wang, Z; Zhang, CY, 2018) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 1.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| "Pulmonary nocardiosis is an infrequent but insidious disease in transplant patients." | 1.31 | Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. ( Adinolfi, LE; Andreana, A; Casillo, R; Durante Mangoni, E; Farina, C; Gambardella, M; Sarnataro, G; Tripodi, MF; Utili, R, 2001) |
| "Ciprofloxacin MICs were 0." | 1.30 | In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients. ( Hamilton, VE; Richards, RM; Thomas, MR, 1998) |
| "The signs of pneumonic plague in sacred baboons infected by aerosol are: fever, hurried breathing, depression and constantly increasing bacteremia." | 1.29 | [Standardization of conditions for the evaluation of effectiveness of antibacterial drugs in pneumonic plague in sacred baboons]. ( Mironin, AV; Paramonov, VE; Romanov, VE; Shabalin, BA; Vasil'ev, NT, 1995) |
| "Ciprofloxacin was administered orally (15 mg/kg of body weight) or intravenously (6 mg/kg) twice a day for at least 10 days during separate treatment periods." | 1.28 | Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ( Christensson, BA; Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1992) |
| "We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung." | 1.28 | Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. ( Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991) |
| "Amikacin and imipenem were the two most effective single agents studied." | 1.28 | Therapy of pulmonary nocardiosis in immunocompromised mice. ( Aulicino, TM; Berkowitz, LB; duBouchet, L; Gombert, ME, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (19.57) | 18.7374 |
| 1990's | 16 (34.78) | 18.2507 |
| 2000's | 10 (21.74) | 29.6817 |
| 2010's | 9 (19.57) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Takeda, S | 1 |
| Nakai, T | 1 |
| Wakai, Y | 1 |
| Ikeda, F | 1 |
| Hatano, K | 1 |
| King, P | 1 |
| Lomovskaya, O | 1 |
| Griffith, DC | 1 |
| Burns, JL | 1 |
| Dudley, MN | 1 |
| Arauzo, B | 1 |
| Lobera, MP | 1 |
| Monzon, A | 1 |
| Santamaria, J | 1 |
| Wang, W | 1 |
| Yang, J | 1 |
| Wu, X | 1 |
| Wan, B | 1 |
| Wang, H | 1 |
| Yu, F | 1 |
| Guo, Y | 1 |
| Su, FY | 1 |
| Srinivasan, S | 1 |
| Lee, B | 1 |
| Chen, J | 1 |
| Convertine, AJ | 1 |
| West, TE | 1 |
| Ratner, DM | 1 |
| Skerrett, SJ | 1 |
| Stayton, PS | 1 |
| Zhang, CY | 1 |
| Gao, J | 1 |
| Wang, Z | 1 |
| Haque, S | 1 |
| Feeney, O | 1 |
| Meeusen, E | 1 |
| Boyd, BJ | 1 |
| McIntosh, MP | 1 |
| Pouton, CW | 1 |
| Whittaker, M | 1 |
| Kaminskas, LM | 1 |
| Patsche, CB | 1 |
| Svensson, E | 1 |
| Wejse, C | 1 |
| Jeon, K | 1 |
| Kwon, OJ | 1 |
| Lee, NY | 1 |
| Kim, BJ | 1 |
| Kook, YH | 1 |
| Lee, SH | 1 |
| Park, YK | 1 |
| Kim, CK | 1 |
| Koh, WJ | 1 |
| Lieberman, TD | 1 |
| Michel, JB | 1 |
| Aingaran, M | 1 |
| Potter-Bynoe, G | 1 |
| Roux, D | 1 |
| Davis, MR | 1 |
| Skurnik, D | 1 |
| Leiby, N | 1 |
| LiPuma, JJ | 1 |
| Goldberg, JB | 1 |
| McAdam, AJ | 1 |
| Priebe, GP | 1 |
| Kishony, R | 1 |
| Veach, RA | 1 |
| Zienkiewicz, J | 1 |
| Collins, RD | 1 |
| Hawiger, J | 1 |
| Fernández-Olmos, A | 1 |
| García-Castillo, M | 1 |
| Maiz, L | 1 |
| Lamas, A | 1 |
| Baquero, F | 2 |
| Cantón, R | 2 |
| Wilson, R | 1 |
| Welte, T | 1 |
| Polverino, E | 1 |
| De Soyza, A | 1 |
| Greville, H | 1 |
| O'Donnell, A | 1 |
| Alder, J | 1 |
| Reimnitz, P | 1 |
| Hampel, B | 1 |
| Van Zonneveld, M | 1 |
| Droogh, JM | 1 |
| Fieren, MW | 1 |
| Gyssens, IC | 1 |
| Van Gelder, T | 1 |
| Weimar, W | 1 |
| Cobos, N | 1 |
| de Gracia, J | 1 |
| Honorato, J | 1 |
| Gartner, S | 1 |
| Alvarez, A | 1 |
| Salcedo, A | 1 |
| Oliver, A | 1 |
| García-Quetglas, E | 1 |
| Caruso, E | 1 |
| Castro, JM | 1 |
| Chamoles, N | 1 |
| Galimberti, R | 1 |
| Jorge, L | 1 |
| Rohwedder, R | 1 |
| Shitrit, D | 1 |
| Baum, GL | 1 |
| Priess, R | 1 |
| Lavy, A | 1 |
| Shitrit, AB | 1 |
| Raz, M | 1 |
| Shlomi, D | 1 |
| Daniele, B | 1 |
| Kramer, MR | 1 |
| Leus, B | 1 |
| Devreese, K | 1 |
| van den Bossche, J | 1 |
| Malfait, R | 1 |
| Polianskaia, GG | 1 |
| Sizova, LS | 1 |
| Efremova, TN | 1 |
| Fridlianskaia, II | 1 |
| Le Huec, JC | 1 |
| Schaeverbeke, T | 1 |
| Chauveaux, D | 1 |
| Moinard, M | 1 |
| Rivel, J | 1 |
| Le Rebeller, A | 1 |
| Lobo, IM | 1 |
| Silva, NF | 1 |
| Assef, MC | 1 |
| Mangini, C | 1 |
| Silva, ML | 1 |
| Bortoletto, ML | 1 |
| Mendonça, JS | 1 |
| Levi, GC | 1 |
| Koul, PA | 1 |
| Wani, JI | 1 |
| Wahid, A | 1 |
| Shah, P | 1 |
| Orenstein, DM | 1 |
| Pattishall, EN | 1 |
| Noyes, BE | 1 |
| Kurland, G | 1 |
| Hartigan, ER | 1 |
| Yu, VL | 2 |
| Fukuoka, Y | 1 |
| Ikeda, Y | 1 |
| Yamashiro, Y | 1 |
| Takahata, M | 1 |
| Todo, Y | 1 |
| Narita, H | 1 |
| Romanov, VE | 1 |
| Vasil'ev, NT | 1 |
| Shabalin, BA | 1 |
| Mironin, AV | 1 |
| Paramonov, VE | 1 |
| Frederiksen, B | 1 |
| Koch, C | 1 |
| Høiby, N | 1 |
| Benator, DA | 1 |
| Kan, V | 1 |
| Gordin, FM | 1 |
| Richards, RM | 1 |
| Hamilton, VE | 1 |
| Thomas, MR | 1 |
| Wolfe, J | 1 |
| Turenne, C | 1 |
| Alfa, M | 1 |
| Harding, G | 1 |
| Thibert, L | 1 |
| Kabani, A | 1 |
| Bald, M | 1 |
| Ratjen, F | 1 |
| Nikolaizik, W | 1 |
| Wingen, AM | 1 |
| Parienti, JJ | 1 |
| Ramakers, M | 1 |
| Charbonneau, P | 1 |
| Tripodi, MF | 1 |
| Adinolfi, LE | 1 |
| Andreana, A | 1 |
| Sarnataro, G | 1 |
| Durante Mangoni, E | 1 |
| Gambardella, M | 1 |
| Casillo, R | 1 |
| Farina, C | 1 |
| Utili, R | 1 |
| Christensson, BA | 1 |
| Nilsson-Ehle, I | 2 |
| Ljungberg, B | 2 |
| Lindblad, A | 2 |
| Malmborg, AS | 2 |
| Hjelte, L | 2 |
| Strandvik, B | 2 |
| Singh, N | 1 |
| Diver, JM | 1 |
| Schollaardt, T | 1 |
| Rabin, HR | 1 |
| Thorson, C | 1 |
| Bryan, LE | 1 |
| Vallée, E | 1 |
| Azoulay-Dupuis, E | 1 |
| Pocidalo, JJ | 1 |
| Bergogne-Bérézin, E | 1 |
| Arvieux, C | 1 |
| Charasse, C | 1 |
| Guilhem, I | 1 |
| Rivalan, J | 1 |
| Le Pogamp, P | 1 |
| Ramée, MP | 1 |
| Gombert, ME | 1 |
| Berkowitz, LB | 1 |
| Aulicino, TM | 1 |
| duBouchet, L | 1 |
| Bosso, JA | 2 |
| Bayer, AS | 1 |
| Nakamura, S | 1 |
| Minami, A | 1 |
| Nakata, K | 1 |
| Kurobe, N | 1 |
| Kouno, K | 1 |
| Sakaguchi, Y | 1 |
| Kashimoto, S | 1 |
| Yoshida, H | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
| Goldfarb, J | 1 |
| Stern, RC | 1 |
| Reed, MD | 1 |
| Yamashita, TS | 1 |
| Myers, CM | 1 |
| Blumer, JL | 1 |
| Black, PG | 1 |
| Matsen, JM | 1 |
| Rubio, TT | 1 |
| Scully, BE | 1 |
| Nakatomi, M | 1 |
| Ores, C | 1 |
| Davidson, S | 1 |
| Neu, HC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis[NCT00930982] | Phase 2 | 124 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total bacterial load was determined in sputum collected before the inhalation of study drug. Sputum samples were either provided by the participant during the respective study visit, or participants had to bring a sputum sample that had been produced within the 4 hours prior to the visit. Induced sputum samples could be collected if the participant was unable to produce a spontaneously expectorated sputum sample of > 2 mL. Imputation method: last observation carried forward (LOCF). CFU: colony forming units, log10: decadic logarithm (NCT00930982)
Timeframe: Baseline and 29 days
| Intervention | log10 of CFU per gram sputum (Mean) |
|---|---|
| Ciprofloxacin Inhale (BAYQ3939) | -2.94 |
| Placebo | -0.32 |
Acute exacerbation was defined according to the joint American Thoracic Society/European Respiratory Society criteria. For detailed information with regard to this definition of acute exacerbation, please refer to the detailed description in the protocol section. The time to an acute exacerbation with antibiotic intervention was determined. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin Inhale (BAYQ3939) | NA |
| Placebo | NA |
Participants were asked to start 24-hour sputum collection samples 24 hours before coming for the respective study visit. Sputum color was assessed as either 'clear', or as 'yellow', 'green' or 'rust', or an assessment of 'no sputum' was made. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 91.7 | 73.2 | 75.5 | 72.8 | 75.0 | 66.6 |
| Placebo | 88.9 | 94.9 | 82.7 | 88.4 | 86.5 | 72.8 |
Participants were asked to start 24-hour sputum collection samples 24 hours before coming for the respective study visit. The volume of the completed sample was determined. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 24.9 | 18.9 | 20.5 | 21.1 | 19.6 | 23.6 |
| Placebo | 30.2 | 30.0 | 27.3 | 22.8 | 22.0 | 25.9 |
Absolute neutrophil count (ANC) was determined from safety blood samples. Missing or invalid values were replaced with the last valid value available. (NCT00930982)
Timeframe: Baseline and up to Day 42
| Intervention | giga/L (Mean) | ||
|---|---|---|---|
| Day 8 | Day 29 | Day 42 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.35 | -0.36 | -0.28 |
| Placebo | -0.03 | 0.59 | 0.24 |
Pulmonary function testing (spirometry) was conducted in accordance with American Thoracic Society standards. FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). Imputation method: last observation carried forward (LOCF). (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | Percent of predicted FEV1 (Mean) | ||||
|---|---|---|---|---|---|
| Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.67 | -0.53 | 1.19 | 0.81 | 0.70 |
| Placebo | -0.14 | -0.22 | -0.26 | -0.24 | -0.50 |
Pulmonary function testing (spirometry) was conducted in accordance with American Thoracic Society standards. FVC was defined as the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, i.e. vital capacity performed with a maximally forced expiratory effort expressed in liters at BTPS. Imputation method: last observation carried forward (LOCF). (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | Percent of predicted FVC (Mean) | ||||
|---|---|---|---|---|---|
| Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.33 | -0.76 | 0.92 | 0.36 | -0.01 |
| Placebo | 0.04 | -1.05 | -1.09 | -1.16 | -1.99 |
High sensitive C-reactive protein (hsCRP) was determined from safety blood samples. Missing or invalid values were replaced with the last valid value available. (NCT00930982)
Timeframe: Baseline and up to Day 42
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| Day 8 | Day 29 | Day 42 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.43 | 0 | -0.16 |
| Placebo | -0.19 | 0 | 0.12 |
Total bacterial load was determined in sputum collected before the inhalation of study drug. Sputum samples were either provided by the participant during the respective study visit, or participants had to bring a sputum sample that had been produced within the 4 hours prior to the visit. Induced sputum samples could be collected if the participant was unable to produce a spontaneously expectorated sputum sample of > 2 mL on Day 8. Imputation method: last observation carried forward (LOCF). CFU: colony forming units, log10: decadic logarithm (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | log10 of CFU per gram sputum (Mean) | |||
|---|---|---|---|---|
| Day 8 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -2.87 | -1.86 | -1.86 | -1.37 |
| Placebo | -0.20 | -0.31 | -0.21 | -0.24 |
Participants completed the Chronic Respiratory Questionnaire - Self Administered Standardized (CRQ-SAS). They were assured that all data would be treated confidentially and that the answers would not have any influence on study drug treatment. Participants completed the questionnaires on their own in a quiet area, without discussing them with study staff or accompanying persons (e.g. friends or relatives) and before being seen by the clinician. The score ranges between 1 and 7, 1 being the worst possible score. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Total score on a scale (Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 29 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 4.88 | 4.99 | 4.94 | 5.01 |
| Placebo | 4.96 | 4.93 | 4.91 | 4.99 |
Participants completed the Saint George's Respiratory Questionnaire (SGRQ). They were assured that all data would be treated confidentially and that the answers would not have any influence on study drug treatment. Participants completed the questionnaires on their own in a quiet area, without discussing them with study staff or accompanying persons (e.g. friends or relatives) and before being seen by the clinician. The score ranges from 0 to 100 with 100 being the worst possible score. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 29 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 43.8 | 41.5 | 40.6 | 40.6 |
| Placebo | 44.7 | 44.8 | 44.1 | 41.6 |
The emergence of new potential respiratory pathogens was evaluated using microbiological analysis. Evaluated was the cumulative number of participants with first appearance of new potential respiratory antigens at each time point. In some cases, participants attended the end of study visit later than Day 84 (up to Day 88). (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Cumulative participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 4 | Day 5 | Day 7 | Day 8 | Day 9 | Day 10 | Day 14 | Day 15 | Day 28 | Day 29 | Day 30 | Day 36 | Day 39 | Day 42 | Day 43 | Day 44 | Day 45 | Day 57 | Day 58 | Day 59 | Day 78 | Day 83 | Day 84 | Day 85 | Day 86 | Day 88 | |
| Ciprofloxacin Inhale (BAYQ3939) | 1 | 1 | 2 | 7 | 7 | 7 | 7 | 7 | 7 | 12 | 14 | 15 | 16 | 18 | 21 | 25 | 26 | 29 | 29 | 30 | 31 | 32 | 33 | 38 | 41 | 43 |
| Placebo | 0 | 2 | 2 | 8 | 10 | 11 | 12 | 13 | 14 | 24 | 30 | 30 | 31 | 33 | 38 | 40 | 41 | 45 | 46 | 47 | 47 | 47 | 47 | 53 | 54 | 54 |
The emergence of resistance (at least two-fold increase of Minimal inhibitory concentration, MIC, vs. baseline values) probably or possibly related to study medication among baseline pathogens was evaluated using microbiological analysis. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Emergence (>= 2* increase of MIC) | Sustained (>= 2* increase of MIC until end) | Transient (Increase in MIC with normalization) | Insufficient follow up | |
| Ciprofloxacin Inhale (BAYQ3939) | 7 | 1 | 5 | 1 |
| Placebo | 1 | 0 | 1 | 0 |
Microbiological response was defined as reduction in bacterial load or eradication (measured as the percentage of participants with positive culture). Missing values were not imputed. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 100.0 | 52.4 | 65.0 | 83.3 | 87.1 | 85.2 |
| Placebo | 100.0 | 88.2 | 91.8 | 86.8 | 96.4 | 92.0 |
Microbiological response was defined as reduction in bacterial load or eradication (measured as the number of participants with positive culture). Missing values were not imputed. Pathogens analyzed: Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Serratia marcescens, Pseudomonas aeruginosa, mucoid, Pseudomonas aeruginosa, non mucoid, Stenotrophomonas maltophilia, Achromobacter xylosoxydans, Moraxella catarrhalis, Haemophilus influenzae (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S. aureus Day 1 | S. aureus Day 8 | S. aureus Day 29 | S. aureus Day 42 | S. aureus Day 56 | S. aureus Day 84 | S. pneumoniae Day 1 | S. pneumoniae Day 8 | S. pneumoniae Day 29 | S. pneumoniae Day 42 | S. pneumoniae Day 56 | S. pneumoniae Day 84 | E. coli Day 1 | E. coli Day 8 | E. coli Day 29 | E. coli Day 42 | E. coli Day 56 | E. coli Day 84 | K. pneumoniae Day 1 | K. pneumoniae Day 8 | K. pneumoniae Day 29 | K. pneumoniae Day 42 | K. pneumoniae Day 56 | K. pneumoniae Day 84 | K. oxytoca Day 1 | K. oxytoca Day 8 | K. oxytoca Day 29 | K. oxytoca Day 42 | K. oxytoca Day 56 | K. oxytoca Day 84 | P. mirabilis Day 1 | P. mirabilis Day 8 | P. mirabilis Day 29 | P. mirabilis Day 42 | P. mirabilis Day 56 | P. mirabilis Day 84 | S. marcescens Day 1 | S. marcescens Day 8 | S. marcescens Day 29 | S. marcescens Day 42 | S. marcescens Day 56 | S. marcescens Day 84 | P. aeruginosa, mucoid Day 1 | P. aeruginosa, mucoid Day 8 | P. aeruginosa, mucoid Day 29 | P. aeruginosa, mucoid Day 42 | P. aeruginosa, mucoid Day 56 | P. aeruginosa, mucoid Day 84 | P. aeruginosa, non mucoid Day 1 | P. aeruginosa, non mucoid Day 8 | P. aeruginosa, non mucoid Day 29 | P. aeruginosa, non mucoid Day 42 | P. aeruginosa, non mucoid Day 56 | P. aeruginosa, non mucoid Day 84 | S. maltophilia Day 1 | S. maltophilia Day 8 | S. maltophilia Day 29 | S. maltophilia Day 42 | S. maltophilia Day 56 | S. maltophilia Day 84 | A. xylosoxydans Day 1 | A. xylosoxydans Day 8 | A. xylosoxydans Day 29 | A. xylosoxydans Day 42 | A. xylosoxydans Day 56 | A. xylosoxydans Day 84 | M. catarrhalis Day 1 | M. catarrhalis Day 8 | M. catarrhalis Day 29 | M. catarrhalis Day 42 | M. catarrhalis Day 56 | M. catarrhalis Day 84 | H. influenzae Day 1 | H. influenzae Day 8 | H. influenzae Day 29 | H. influenzae Day 42 | H. influenzae Day 56 | H. influenzae Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 8 | 4 | 5 | 6 | 8 | 5 | 7 | 2 | 0 | 3 | 1 | 1 | 2 | 2 | 2 | 0 | 1 | 1 | 5 | 0 | 0 | 0 | 1 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 12 | 7 | 9 | 9 | 6 | 4 | 20 | 6 | 10 | 12 | 10 | 13 | 2 | 0 | 2 | 2 | 4 | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 5 | 0 | 0 | 1 | 1 | 1 | 14 | 1 | 1 | 1 | 3 | 4 |
| Placebo | 17 | 7 | 10 | 9 | 5 | 5 | 2 | 4 | 4 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 1 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 2 | 0 | 16 | 15 | 16 | 12 | 6 | 5 | 19 | 17 | 14 | 12 | 9 | 6 | 3 | 3 | 3 | 1 | 3 | 1 | 3 | 2 | 1 | 0 | 1 | 2 | 3 | 3 | 6 | 2 | 2 | 2 | 16 | 12 | 11 | 7 | 8 | 8 |
4 reviews available for ciprofloxacin and Lung Diseases
| Article | Year |
|---|---|
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cep | 2005 |
Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Lung | 1997 |
Successful treatment of pulmonary infection due to Mycobacterium chelonae: case report and review.
Topics: Amikacin; Cefoxitin; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Lung Diseases; Middle | 1992 |
Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; Cystic Fibrosi | 1989 |
7 trials available for ciprofloxacin and Lung Diseases
| Article | Year |
|---|---|
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bacterial Load; Bronchiectasis; Ciprofloxac | 2013 |
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Carrier State; Child; Child, Presch | 1997 |
Use of ciprofloxacin in cystic fibrosis patients.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Lung Diseases; Ma | 1989 |
Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
Topics: Adolescent; Adult; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Female; Humans; Kinetic | 1987 |
Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Azlocillin; Bacterial Infections; Ciprofloxacin; Clinical Trials as To | 1987 |
Ciprofloxacin: comparative data in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Therap | 1987 |
Ciprofloxacin therapy in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Child; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug | 1987 |
35 other studies available for ciprofloxacin and Lung Diseases
| Article | Year |
|---|---|
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
Topics: Animals; beta-Lactamases; Burns; Cephalosporins; Drug Resistance, Multiple, Bacterial; Lung Diseases | 2007 |
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, M | 2010 |
Dry powder formulation for pulmonary infections: Ciprofloxacin loaded in chitosan sub-micron particles generated by electrospray.
Topics: A549 Cells; Administration, Inhalation; Anti-Bacterial Agents; Chitosan; Ciprofloxacin; Humans; Lung | 2021 |
Difference in drug susceptibility distribution and clinical characteristics between
Topics: Adult; Aged; Anti-Bacterial Agents; China; Ciprofloxacin; Clarithromycin; Cough; Doxycycline; Drug R | 2021 |
Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Ciprofloxacin; Delayed-Action Preparatio | 2018 |
Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management.
Topics: Amides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Proteins; | 2018 |
Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats.
Topics: Animals; Anti-Bacterial Agents; Bleomycin; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Cytokines; I | 2019 |
Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; | 2014 |
Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefoxitin; Chemical and Drug Induced | 2009 |
Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes.
Topics: Adaptation, Biological; Anti-Bacterial Agents; Bacteremia; Burkholderia; Burkholderia Infections; Ci | 2011 |
Lethality in a murine model of pulmonary anthrax is reduced by combining nuclear transport modifier with antimicrobial therapy.
Topics: Active Transport, Cell Nucleus; Animals; Anthrax; Anti-Infective Agents; Cell-Penetrating Peptides; | 2012 |
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin; | 2012 |
Yersinia pseudotuberculosis bacteraemia in a kidney transplant patient.
Topics: Anti-Infective Agents; Bacteremia; Ciprofloxacin; Cyclosporine; Humans; Immunosuppressive Agents; Ki | 2002 |
Penetration of ciprofloxacin into human lung tissue after oral and i.v. dosing.
Topics: Administration, Oral; Anti-Infective Agents; Ciprofloxacin; Humans; Injections, Intravenous; Kinetic | 1989 |
Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Topics: Adult; Antibiotics, Antitubercular; Ciprofloxacin; Clarithromycin; Cycloserine; Ethambutol; Ethionam | 2006 |
Factor V inhibitor: case report.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Blood Coagulation Tests; Ciprofloxacin; Disease Progressi | 2006 |
[A cytogenetic study of the Chinese hamster lung cell line V-79 infected with Mycoplasma arginini and decontaminated using ciprofloxacin].
Topics: Animals; Cell Line; Chromosome Aberrations; Ciprofloxacin; Cricetinae; Cricetulus; Drug Evaluation, | 1994 |
[Epicondylitis induced by fluoroquinolones in athletes. Apropos of 2 cases].
Topics: Ciprofloxacin; Humans; Lung Diseases; Magnetic Resonance Spectroscopy; Male; Middle Aged; Orchitis; | 1994 |
Oral ciprofloxacin for treatment of severe infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacteremia; Bacterial Infections; Ciprofloxaci | 1993 |
Pulmonary manifestations of multidrug-resistant typhoid fever.
Topics: Adolescent; Adult; Child; Ciprofloxacin; Drug Resistance, Microbial; Female; Humans; India; Lung Dis | 1993 |
Safety of ciprofloxacin in children with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Alkaline Phosphatase; Child; Ciprofloxacin; Cystic Fibrosis; Drug | 1993 |
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases | 1993 |
[Standardization of conditions for the evaluation of effectiveness of antibacterial drugs in pneumonic plague in sacred baboons].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Body Temperature Regulation; Ciprofloxacin; D | 1995 |
In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combinati | 1998 |
Mycobacterium branderi from both a hand infection and a case of pulmonary disease.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Clarithromycin; DNA, Ribosomal; Drug Therapy, C | 2000 |
Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis.
Topics: Acute Kidney Injury; Adolescent; Anti-Infective Agents; Ciprofloxacin; Creatinine; Cystic Fibrosis; | 2001 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Intensive Care Units; Lung | 2001 |
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage; Ciprofloxacin; Female; Heart Transplantation; | 2001 |
Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Ciprofloxacin; Cystic Fibrosis; Dr | 1992 |
Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.
Topics: Bacterial Outer Membrane Proteins; beta-Lactamases; Carbon Radioisotopes; Chloramphenicol O-Acetyltr | 1991 |
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseas | 1991 |
[Acute kidney failure due to tubulo-interstitial nephropathy after treatment with ciprofloxacin].
Topics: Acute Kidney Injury; Aged; Ciprofloxacin; Humans; Lung Diseases; Male | 1991 |
Therapy of pulmonary nocardiosis in immunocompromised mice.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Cortisone; Female; Humans; Imi | 1990 |
Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Ciprofloxacin; Cystic Fibrosis; Dr | 1989 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |